Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study.
BACKGROUND Everolimus-based endocrine therapy is used for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) metastatic breast cancer after cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment, but factors associated with treatment durability remain unclear. We...